Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

BIO Applauds Senate Passage of Advancing Hope Act

Biotechnology Innovation Organization
Posted on: 24 Sep 16

Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood released the following statement today regarding Senate passage of the Advancing Hope Act of 2016:

“BIO applauds yesterday’s action by the Senate to pass the Advancing Hope Act of 2016, which would extend the Rare Pediatric Priority Review Voucher (PRV) Program – which was scheduled to expire on September 30th – through the end of the year. The program is a critical incentive in promoting research into rare diseases affecting children, and has been a tremendous success since its enactment in 2012 – helping to spur the development and approval of six new therapies for seven rare diseases that previously lacked an FDA-approved therapy. We urge the House of Representatives to swiftly take up and pass this important legislation before the next Congressional recess.

“While action to extend the program through the end of the year is a welcome short-term step, a lengthier reauthorization is necessary if the program is to continue to promote research to benefit children with rare diseases. Drug development is a long, complex and expensive process, frequently requiring over a decade of research and clinical trials to move a potential medicine from the research lab to FDA approval. Drug companies plan their research programs over years and decades, not weeks and months. As such, it is important for an incentive such as the Rare Pediatric PRV to be reliably available in the long-term if it is to spur research into otherwise neglected disease areas. We hope that in the coming months, both Houses of Congress will find a solution for a long-term reauthorization of this critical program.

“We applaud Senators Casey and Isakson, as well as Chairman Alexander and Ranking Member Murray, for their leadership in promoting medical research for children with rare and often devastating illnesses.”

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Upcoming BIO Events


BIO IP & Diagnostics Symposium
September 29, 2016
Alexandria, VA

BIO Latin America Conference
October 26-28, 2016
Grand Hyatt São Paulo, Brazil


BIO Investor Forum
October 18-19, 2016
San Francisco, CA

BIO International Convention
June 19-22
San Diego, CA

View source version on

Business Wire

Last updated on: 24/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.